{"prompt": "['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-004', '(Sanofi Genzyme EFC14769)', '27 Jun 2018', '6.3.1.3.', 'Bleeding Episode Management Following Discontinuation of Fitusiran', 'Patients who opt to discontinue fitusiran may resume standard on-demand dosing with factor', 'concentrates (FVIII, FIX) when their AT residual activity level returns to approximately 60%', '(per the central laboratory). An earlier restart of standard treatment may be considered in', 'conjunction with consultation from the study Medical Monitor, if a strong medical need arises', '(eg, increased frequency of bleeding). If full doses of factor or BPA are required to achieve', 'hemostasis prior to AT recovery of approximately 60% residual activity per the central', 'laboratory, AT replacement should be considered.', '6.3.2.', 'Other Concomitant Medications', 'If patients use nonsteroidal anti-inflammatory drugs intermittently or chronically, they must be', 'able to tolerate them and have had no previous side effects (eg, gastric distress or bleeding).', 'Use of >4 g acetaminophen per day is not permitted.', 'Treatment for HIV is permitted and must be recorded as concomitant medication.', 'Standard vitamins and topical medications are permitted. However, topical steroids must not be', 'applied anywhere near the injection site(s) unless medically indicated.', \"Any concomitant medication that is required for the patient's welfare may be prescribed by the\", 'Investigator. However, it is the responsibility of the Investigator to ensure that details regarding', 'the medication are recorded on the eCRF. Concomitant medication will be coded using an', 'internationally recognized and accepted coding dictionary.', '6.4.', 'Assessment of Coagulation Parameters at the Time of a Bleed', 'Any patient who presents to the clinical study center for evaluation of symptoms that are', 'suspected as characteristic of a bleeding episode, the patient should be assessed by the', 'Investigator to determine whether symptom(s) require treatment. If treatment is required, blood', 'samples should be collected predose and postdose and assessments performed as scheduled in', 'Table 2.', 'If a patient presents following administration of factor or BPAs at home and within 48 hours of', 'the dose, and no further treatment is given at the center, AT and the postdose assessments in', 'Table 2 should be obtained in a single draw at any time during the visit.', '6.5.', 'Monitoring and Management of Thrombotic Events', \"Given safety events observed thus far and the possible thrombotic risk associated with fitusiran's\", 'AT lowering mechanism, which may be increased with concurrent use of factor replacement', 'products or BPAs, there should be a low threshold to evaluate any signs and symptoms', 'consistent with thrombosis, including symptoms consistent with CVST. Symptoms of', 'thrombosis may include a severe or persistent headache, headache with nausea and vomiting,', 'chest pain/tightness, coughing up blood, trouble breathing, abdominal pain, fainting or loss of', 'consciousness, vision problems, and swelling or pain in the arms or legs.', 'If signs and symptoms consistent with thrombosis are present, the Investigator should evaluate', 'the patient for thrombosis, including appropriate imaging studies. For the diagnosis of CVST', 'Property of the Sanofi Group - strictly confidential', '50', '(electronic 1.0)']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-004', '(Sanofi Genzyme EFC14769)', '27 Jun 2018', 'magnetic resonance imaging venogram (MRV) or computed tomography venogram (CTV) are', 'recommended. [7]', 'If a patient develops a thrombosis while on fitusiran, AT reversal is recommended in', 'combination with factor or BPA replacement and appropriate anticoagulation. AT reversal', 'should follow labeled product recommendations for the prevention of perioperative thrombosis', 'in patients with AT deficiency, and patient doses individualized to target 80-120% AT activity.', 'The use of plasma derived AT may be preferable to recombinant AT, given its longer half-life.', 'It is recommended that cases of thrombosis are discussed with the study Medical Monitor and', 'Clinical Advisor (see Section 7.5.6.1 for further information regarding Adverse Events of', 'Special Interest).', '6.6.', 'Elective and/or Emergency Surgery', 'If an urgent need for surgery arises during the study period, the study Medical Monitor will be', 'informed and the perioperative hemostatic treatment plan will be communicated to the study', 'Medical Monitor unless clinical circumstances do not allow.', 'It is recommended that, when possible, any elective non-dental major surgery be performed at a', 'clinical study center.', 'For reference, see Appendix (Section 11.2.1) for definitions of minor and major surgery.', 'Perioperative Treatment Plan', 'In patients in both the on-demand arm and the fitusiran treatment arm undergoing surgery, a', 'written perioperative treatment plan will be reviewed with the study Medical Monitor before', 'conducting the procedure, unless clinical circumstances do not allow. In patients on fitusiran,', 'the perioperative treatment plan should be developed using the same principles as bleed', 'management described in Section 6.3.1 and the guideline below:', 'If the clinical circumstance is such that the recommended doses and/or dose intervals in', 'Table 4 are deemed insufficient for hemostasis, consider AT replacement and manage', 'thrombotic risk as per Investigator practice for a hemophilia patient undergoing that', 'particular surgery.', 'Non-pharmacologic methods of thromboprophylaxis should also be employed as', 'clinically indicated.', 'Fitusiran Treatment During the Perioperative Evaluation Period', 'For reference, see Appendix (Section 11.2.1) for definitions of minor and major surgery.', 'If the need for a major surgery arises during the trial and the procedure is not an emergency or', 'urgent, it is recommended that the procedure be postponed until after completion of the trial.', 'For minor operative procedures, dosing with fitusiran may continue uninterrupted.', 'If the need for emergency or urgent major surgery arises during the trial, the patient should be', 'managed medically according to the guidelines above. If a fitusiran dose is scheduled to occur', 'on or in close proximity to the day of surgery, or anytime during the perioperative period, the', 'dose should be withheld. The Perioperative Period is defined as the day of the surgery through', 'Property of the Sanofi Group - strictly confidential', '51', '(electronic 1.0)']\n\n###\n\n", "completion": "END"}